Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.  The company’s initial program focuses on inhibiting RecA, a key enzyme in bacterial DNA repair as well as in the development and transmission of antibiotic resistance.  Prototype RecA inhibitors potentiate the killing of a wide variety of pathogenic bacteria by a broad range of bactericidal antibiotics.

fake ray bans cheap ray bans montblanc pens outlet christian louboutin replica